LitAlert ~~ GeneLit.com

    • Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?
    • Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby JE.
    • Breast. 2022 Dec 6:S0960-9776(22)00193-X. doi: 10.1016/j.breast.2022.12.001. Epub ahead of print.
    • Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
    • Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
    • Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.
    • A Single Variant in Pri-miRNA-155 Associated with Susceptibility to Hereditary Breast Cancer Promotes Aggressiveness in Breast Cancer Cells.
    • Landeros N, Gonzalez-Hormazabal P, Pérez-Moreno P, Tapia JC, Jara L.
    • Int J Mol Sci. 2022 Dec 6;23(23):15418. doi: 10.3390/ijms232315418.
    • Non-parametric estimation of the age-at-onset distribution from a cross-sectional sample.
    • Mandal S, Qin J, Pfeiffer RM.
    • Biometrics. 2022 Dec 5. doi: 10.1111/biom.13804. Epub ahead of print.
    • Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
    • Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES.
    • Nat Commun. 2022 Dec 5;13(1):7495. doi: 10.1038/s41467-022-35245-x.
    • Targeting DNA damage response pathways in cancer.
    • Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M.
    • Nat Rev Cancer. 2022 Dec 5. doi: 10.1038/s41568-022-00535-5. Epub ahead of print.
    • Review
    • CHEK2 Pathogenic Germline Variants in Patients With NSCLC.
    • Sorscher S.
    • JTO Clin Res Rep. 2022 Nov 19 [eCollection 2022 Dec];3(12):100439. doi: 10.1016/j.jtocrr.2022.100439.

    •• Original research:

    A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.